Zimmer Biomet Holdings First Quarter 2025 Earnings: EPS Beats Expectations

Zimmer Biomet Holdings (NYSE:ZBH) First Quarter 2025 Results

Key Financial Results

• Revenue: US$1.91b (up 1.1% from 1Q 2024).
• Net income: US$182.0m (up 5.6% from 1Q 2024).
• Profit margin: 9.5% (in line with 1Q 2024).
• EPS: US$0.92 (up from US$0.84 in 1Q 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Zimmer Biomet Holdings. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zimmer Biomet Holdings EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.1%.

Looking ahead, revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 11% from a week ago.

Valuation

Following the latest earnings results, Zimmer Biomet Holdings may be undervalued based on 6 different valuation benchmarks we assess. To access our thorough examination of analyst consensus click here and discover the expected future direction of the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.